FDA Authorizes First Device to Continuously Monitor Glucose and Ketones

Why it matters locally: Virginia residents with diabetes, particularly the significant portion of the population affected by the condition, will now have access to a new continuous monitoring system that could improve disease management.

The U.S. Food and Drug Administration has authorized the Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System. This authorization marks the first time a wearable device has gained approval to continuously monitor both ketone levels and blood sugar. Individuals aged two years and older who live with diabetes can now use this system. The device provides continuous data on these two biomarkers.